Aethlon Medical Inc
NASDAQ:AEMD

Watchlist Manager
Aethlon Medical Inc Logo
Aethlon Medical Inc
NASDAQ:AEMD
Watchlist
Price: 1.74 USD -4.92% Market Closed
Market Cap: $1.7m

Aethlon Medical Inc
Other Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Aethlon Medical Inc
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
Aethlon Medical Inc
NASDAQ:AEMD
Other Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Other Items
-$1.8B
CAGR 3-Years
-7%
CAGR 5-Years
N/A
CAGR 10-Years
-1%
Stryker Corp
NYSE:SYK
Other Items
-$4.1B
CAGR 3-Years
-21%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Abbott Laboratories
NYSE:ABT
Other Items
-$251m
CAGR 3-Years
N/A
CAGR 5-Years
-46%
CAGR 10-Years
N/A
IDEXX Laboratories Inc
NASDAQ:IDXX
Other Items
$2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Intuitive Surgical Inc
NASDAQ:ISRG
Other Items
$1.2B
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Aethlon Medical Inc
Glance View

Market Cap
1.7m USD
Industry
Health Care

Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 10 full-time employees. The firm operates through two segments: Aethlon and ESI. The Aethlon segment represents its therapeutic business activities. The ESI segment represents its diagnostic business activities. The firm's product, Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The Aethlon Hemopurifie is designed for the single-use removal of exosomes and life-threatening viruses from the human circulatory system. In cancer, the Aethlon Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis. The Company, through its subsidiary Exosome Sciences, Inc. (ESI) is developing exosome-based biomarkers in patients with, or at risk for, a number of cancers.

AEMD Intrinsic Value
4.07 USD
Undervaluation 57%
Intrinsic Value
Price

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett